Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 8930 results

  1. Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death

    In development Reference number: GID-IPG10437 Expected publication date: TBC

    Interventional procedures guidance
    In development

  2. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  3. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tildrakizumab for treating active psoriatic arthritis [ID6724]

    Awaiting development Reference number: GID-TA11807 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development Reference number: GID-TA10911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment

    In development Reference number: GID-HTE10067 Expected publication date: TBC

    Health technology evaluations
    In development

  7. Surgical mesh for treatment of non-primary ventral hernias

    In development Reference number: GID-HTG10165 Expected publication date: TBC

    HealthTech guidance
    In development

  8. Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]

    Awaiting development Reference number: GID-TA12007 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [TSID12390]

    Awaiting development Reference number: GID-TA12008 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. GNT0006 ATA-100 for treating FKRP-related limb girdle muscular dystrophy R9 [TSID12384]

    Awaiting development Reference number: GID-TA12009 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen in people 5 years and over [TSID12379]

    Awaiting development Reference number: GID-TA12010 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Lemborexan for treating insomnia [TSID12397]

    Awaiting development Reference number: GID-TA12011 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [TSID12395]

    Awaiting development Reference number: GID-TA12013 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Nipocalimab for treating generalised myasthenia gravis in people 2 to 17 yearslimab for Myasthenia gravis [TSID12382]

    Awaiting development Reference number: GID-TA12015 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Olezarsen for treating severe hypertrglyceridaemia [TSID12387]

    Awaiting development Reference number: GID-TA12016 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development